Get started
ERIS LIFESCIENCES LTDERIS LIFESCIENCES LTDERIS LIFESCIENCES LTD

ERIS LIFESCIENCES LTD

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

ERIS trade ideas

Eris Lifesciences Ltd. - Swing Trade SetupWe have a potential long trade opportunity in Eris Lifesciences with a defined entry and target. Entry Price: 1368.40 (Confirmed after the 15-minute candle broke above the entry zone at 1350) Target: 1624 Stop Loss: 1213.05 (This stop loss is considered valid if a daily candle closes below this level) This trade setup offers a solid risk-to-reward ratio with the target level at 1624. As always, manage risk according to your trading plan. Disclaimer: This analysis is for educational purposes only and not financial advice. Trade responsibly and use proper risk management.
NSE:ERISLong
by gupshupblog
SWING IDEA - ERISStock is currently trading near its Multi Year Support/Resistance zone of 836. While 836 has been a strong Resistance/Rejection point twine in 2018 and 2021, this has turned out to be a good Support point currently since Sep 2023 during multiple revisits. MACD Cross is also under play at this time. If all goes well, the stock could start seeing some new highs in the coming weeks. Stock has also had a good Earning report this past week, so lets hope for a move upward. Note: Stock has been consolidating in the same zone for nearly 6 months now. With good volumes, it could very well see new highs.
NSE:ERISLong
by thepranam
ERIS Lifesciences Ltd Targets in chart - SL 726 FUNDAMENTALS : Market Cap ₹ 11,116 Cr. Current Price ₹ 817 Stock P/E 29.7 Book Value ₹ 161 Dividend Yield 0.90 % ROCE 17.0 % ROE 18.2 % Face Value ₹ 1.00 Promoter holding 52.9 % EPS last year ₹ 28.1 EPS latest quarter ₹ 6.98 Debt ₹ 877 Cr. Pledged percentage 11.4 % Net CF ₹ -2.34 Cr. Price to Cash Flow 38.1 Free Cash Flow ₹ -550 Cr. Debt to equity 0.40 OPM last year 31.8 % OPM 5Year 34.5 % Reserves ₹ 2,182 Cr. Price to book value 5.06 Int Coverage 12.5 PEG Ratio 5.77 Price to Sales 6.34 Sales growth 3Years 16.2 % Profit Var 3Yrs 8.62 %
NSE:ERISLong
by madhu2811
ERIS Breaks Cup & Handle Resistance: What's Next?This content is for educational purposes only. ERIS has broken above the handle's resistance with a powerful candle, and this upward move is backed by strong volume. It could reach the target soon. I'll share straightforward charts to make it easy for everyone to understand. Stay tuned for more ideas like this. Meanwhile, please like, share, and follow :) Thanks, Wayfarer Keep learning and earning. Disclaimer: We are not registered financial advisors, and the views shared here are personal opinions. It's important to consult with your financial advisors before making any investment decisions.
NSE:ERISLong
by wayfarerTrades
Eris Lifesciences Triangle ConsolidationEris Lifesciences has been consolidating effectively within a triangle pattern, finding strong support at the trendlines. This presents an ideal opportunity for accumulation, either upon breakout or currently, with a stop loss positioned below the supporting trendline. If you're getting in now, use a stop loss around 800. If you're buying during the breakout, adjust your stop accordingly. Aim for a risk-reward ratio of 1:2 or 1:3. There's big potential for gains.
NSE:ERISLong
by Cyril-Richard
Eris looking attractive.Eris Lifesciences Ltd. is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. Eris Lifesciences Ltd CMP is 917.3. The Negative aspects of the company are High Valuation (P.E. = 32.2), Declining annual net profit, declining cash from operations annual, FIIs are decreasing stake, MFs are decreasing stake, High promoter pledge, Promoter Holding decreasing. The positive aspects of the company are No debt. Entry can be taken after closing above 936. Targets in the stock will be 952 and 972. The long-term target in the stock will be 988 and 1020. Stop loss in the stock should be maintained at Closing below 806. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:ERISLong
by Happy_Candles_Investment
Eris Lifesciences Ltd *Eris Lifesciences Ltd.* C&H Formation on Yearly Basis. C&H Price Trendline BreakOut. Should Sustain. Major Resistance at 820/849. Once Crosses / Sustains. Then Good to Go. RSI: 1H < D>W>M Note: Promoters Pledge at 11.4% Forayed in Dermatology in FY22. Acquired Domestic Formulations business of Strides. Acquired Brands from Glenmark & DRL. Spike in Debt. Trail SL with Upside. Book Profit as per Risk Appetite. Do Your Own Research as well. This is an Opinion. Happy Investing 😇
NSE:ERISLong
by IdeasNeosagi
ERIS LIFESCIENCES LTD.The stock is forming Cup and Handle pattern on charts and if we take handle to complete as our target then it's almost 10-12% returns, which I expect it to give in around 2 months time. If you can keep the stock for short to medium term then you can even see the stock hitting 4 digit mark. The fundamentals of the company is good. Though the promoters have decreased there holdings a little but FIIs and DIIs have increased there holdings which is a positive sign. Sales figures QoQ and YoY have also gone up. Reserve and Surplus have also increased which is also a positive sign. Contingent liabilities of the company stands minimal at 26 Crores which is almost negligible. Debt Equity ratio of 0.02 signals a healthy balance sheet. There are few negatives but so many positives along with current momentum in stock can't be overlooked. Surely a stock to watch out for. I am not a SEBI registered analyst. The view here is my personal view and is not a trading or investment advise to anyone. Please consult your financial advisors before making any position.
NSE:ERIS
by abhisarawgi